Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 64

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 64
---
 as a hiring incentive and are typically granted within the month following the date a new employee commences employment with us. Our annual equity awards are granted on a predetermined annual schedule, and we do not take material nonpublic information into account when determining the timing and terms of equity awards. We do not grant equity awards, including stock options, in anticipation of the release of material nonpublic informationand we do not timethe release of material nonpublic information based on equity award grant dates or for the purpose of affecting the value of executive compensation. Further, during the 2024 fiscal year, we did not grant any stock options to our named executive officers. Advisory Vote on Executive Compensation Our most recent advisory vote on named executive officer compensation took place at our 2024 annual meeting of shareholders. Of the votes cast by our shareholders at the meeting, 99% voted “For” a non-binding advisory resolution approving the compensation of our named executive officers, as disclosed in the proxy

40

TABLE OF CONTENTS

statement for that meeting. Our compensation committee reviewed the results of the 2024 advisory vote and viewed the high level of shareholder support as an affirmation of our compensation policies. Our compensation committee concluded that no revisions were necessary to our overall named executive officer compensation program or philosophy as a result of the advisory vote.

**Pay-Versus-Performance**

As required by Section 952(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation S-K, we are providing the following information about the relationship between executive compensation actually paid and our financial performance for each of the last three completed fiscal years. In determining the “compensation actually paid” to our named executive officers (or “NEOs”), we are required to make various adjustments to amounts that have been previously reported in the Summary Compensation Table in previous years, as the SEC’s valuation methods for this disclosure differ from those required in the Summary Compensation Table. For our NEOs other than our principal executive officer (the “PEO”), compensation is reported as an average.

| Year | ​ | ​ | SummaryCompensationTable Total forPEO(1) |   |           |   | ​ | ​ | CompensationActually Paid toPEO(2) |   |           |   | ​ | ​ | Average SummaryCompensationTable Total forNon-PEO NEOs(3) |   |           |   | ​ | ​ | AverageCompensationActually Paid toNon-PEO NEOs(4) |   |           |